vatalanib has been researched along with zd 6474 in 28 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (zd 6474) | Trials (zd 6474) | Recent Studies (post-2010) (zd 6474) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 623 | 88 | 413 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (64.29) | 29.6817 |
| 2010's | 10 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bold, G; Brüggen, J; Furet, P; Haberey, M; Huth, A; Krüger, M; Manley, PW; Menrad, A; Mestan, J; Meyer, T; Ottow, E; Schnell, CR; Seidelmann, D; Siemeister, G; Thierauch, KH; Wood, J | 1 |
| Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
| Brown, ML; Cheung, M; Crosby, RM; Epperly, AH; Harris, PA; Hunter, RN; Johnson, JH; Kumar, R; Liu, W; Luttrell, DK; Nolte, RT; Stafford, JA; Veal, JM; Wang, L | 1 |
| Kiselyov, AS; Piatnitski, E; Semenov, VV; Semenova, M | 2 |
| Annable, T; Cheung, K; Discafani, C; Dushin, RG; Floyd, MB; Fraser, H; Ingalls, C; Johnson, BD; Loganzo, F; Marini, J; Musto, S; Nilakantan, R; Nittoli, T; Ravi, M; Siegel, MM; Tan, X; Wissner, A | 1 |
| Kiselyov, AS; Ouyang, S; Piatnitski, E; Semenov, VV; Semenova, M | 1 |
| Kiselyov, AS; Milligan, D; Semenov, VV; Semenova, M | 1 |
| Kiselyov, AS; Kisliy, VP; Piatnitski, EL; Samet, AV; Semenov, VV | 1 |
| Cheung, K; Dushin, RG; Floyd, MB; Fraser, HL; Ingalls, CL; Loganzo, F; Nittoli, T; Ravi, MR; Tan, X; Wissner, A | 1 |
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Jeong, KW; Kim, MS; Kim, Y; Lee, GS; Lee, K; Lee, Y; Song, JY | 1 |
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Russu, WA; Shallal, HM | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Abou El Ella, DA; Abou-Seri, SM; Ali, MM; Eldehna, WM | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Rosen, LS | 1 |
| Shiotsu, Y | 1 |
| Herbst, RS; Onn, A; Sandler, A | 1 |
| Soff, G; Zakarija, A | 1 |
| Kiselyov, AS; Milligan, D; Ouyang, X | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Lee, CB; Socinski, MA | 1 |
| Batey, MA; de Brito, LR; Hall, AG; Irving, JA; Jackson, G; Leung, HY; Maitland, H; Newell, DR; Squires, MS; Zhao, Y | 1 |
| Döme, B; Török, S | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Adamczak, J; Chatterjee, S; Florin, A; Franz, T; Heukamp, LC; Hinze, Y; Neumaier, B; Schöttle, J; Siobal, M; Ullrich, RT; Wieczorek, C | 1 |
8 review(s) available for vatalanib and zd 6474
| Article | Year |
|---|---|
Inhibitors of the vascular endothelial growth factor receptor.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phthalazines; Piperidines; Pyridines; Pyrroles; Quinazolines; Recombinant Proteins; RNA, Catalytic; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2002 |
[Current screening for molecular target therapy of cancer].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib | 2003 |
Angiogenesis and lung cancer: prognostic and therapeutic implications.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2005 |
Update on angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2005 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
20 other study(ies) available for vatalanib and zd 6474
| Article | Year |
|---|---|
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.
Topics: Administration, Oral; Amides; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; CHO Cells; Cricetinae; Enzyme Inhibitors; Female; Humans; Isoquinolines; Lymphatic Metastasis; Melanoma; Mice; ortho-Aminobenzoates; Phosphorylation; Receptors, Vascular Endothelial Growth Factor | 2002 |
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.
Topics: Adenosine Triphosphate; Angiogenesis Inhibitors; Aniline Compounds; Animals; Binding Sites; Cell Proliferation; Cells, Cultured; Crystallography, X-Ray; Dogs; Humans; Ligands; Male; Mice; Models, Molecular; Oxazoles; Rats; Rats, Sprague-Dawley; Solubility; Structure-Activity Relationship; Umbilical Veins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2005 |
N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.
Topics: Amides; Animals; CHO Cells; Cricetinae; Enzyme Inhibitors; Inhibitory Concentration 50; Molecular Structure; Thiazoles; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.
Topics: Adenosine Triphosphate; Angiogenesis Inhibitors; Animals; Benzoquinones; Binding Sites; Cell Line; Female; Glutathione; Humans; Kinetics; Mice; Mice, Nude; Models, Molecular; Molecular Conformation; Phosphorylation; Protein Binding; Protein Structure, Tertiary; Quantum Theory; Quinazolines; Spectrometry, Mass, Electrospray Ionization; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2005 |
Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.
Topics: Imidazoles; Inhibitory Concentration 50; Molecular Structure; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
Topics: Adenosine Triphosphate; Benzamides; Binding Sites; Fluorescence; Humans; Lipids; Models, Molecular; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template.
Topics: Caco-2 Cells; Enzyme Inhibitors; Humans; Models, Molecular; Pyridines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2.
Topics: Adenosine Triphosphate; Azoles; Binding, Competitive; Caco-2 Cells; Cell Membrane Permeability; Humans; Inhibitory Concentration 50; Intestinal Absorption; Structure-Activity Relationship; Substrate Specificity; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
Topics: Adenosine Triphosphate; Binding Sites; Biological Assay; Cells, Cultured; ErbB Receptors; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
Topics: Drug Evaluation, Preclinical; Models, Molecular; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation.
Topics: Antineoplastic Agents; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Male; Molecular Docking Simulation; Phthalazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates.
Topics: Adenosine Triphosphate; Amides; Azoles; Binding, Competitive; Caco-2 Cells; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Models, Chemical; Phthalazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Phthalazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Mice, Nude; Multimodal Imaging; Phthalazines; Piperidines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2014 |